A Phase 4 interventional study of Temozolomide and Radiotherapy in Glioblastoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.
Among the 232 studies testing temozolomide in Glioblastoma, this one is the 41st largest by enrollment of the 221 interventional ones that give a count, is one of 11 that started in 2008, is one of 2 in phase 4, and was the 80th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 16+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 110 · Phase 2 140 · Phase 3 16 · Phase 4 2
First in 1997; this study’s year is marked. 11 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 41 across the 221 interventional studies. Of the 168 that completed or were terminated, 69 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 232 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
13 studies in Glioblastoma by Merck & Co., Inc: none open now, 1 under way, none of them phase 3. Of 12 finished, 8 (67%) have results posted.
Among the 13 studies in Glioblastoma by Merck & Co., Inc, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is the only one in phase 4, and was the 5th registered.
Merck & Co., Inc’s Glioblastoma studies by the year they started, since 2004.
5 of the studies testing temozolomide in Glioblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT04019262John FlickingerShort Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | 2026-12 |
| NCT04623931M.D. Anderson Cancer CenterChemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | 2026-12-31 |
| NCT07193654Second Affiliated Hospital, School of Medicine, Zhejiang UniversityStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | 2027-04-01 |
| NCT06297512Iacopo SardiEvaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | 2027-11-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 232 studies testing temozolomide in Glioblastoma, from their registry updates:
Among Merck & Co., Inc’s 13 in Glioblastoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to evaluate the efficacy and safety of early postsurgery temozolomide chemotherapy followed by the standard temozolomide regimen, compared to the standard regimen alone, for the treatment of patients with newly diagnosed glioblastoma multiforme.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Only the patients who meet all these criteria can be enrolled in the study:
Laboratory test values must satisfy the following criteria:
Exclusion Criteria:
Patients will not be enrolled if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard therapy regimen: Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m\^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m\^2/day, and may be increased to 200 mg/m\^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used. Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks.
Drug: Temozolomide · Radiation: Radiotherapy
Early postsurgery temozolomide chemotherapy plus standard regimen: Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m\^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen). Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks.
Drug: Temozolomide · Radiation: Radiotherapy
Also known as: Temodal, Temodar, SCH 052365
Also known as: Irradiation, radiation therapy
Overall Survival (OS)
OS was defined as the time from randomization to death. OS was calculated by the Kaplan-Meier method.
Time frame: Up to 2 years
Progression-Free Survival (PFS)
PFS was defined as the length of time from randomization to disease progression (the length of time during which the cancer did not get worse) or death. PFS was calculated by the Kaplan-Meier method.
Time frame: Up to 2 years
Objective Tumor Assessment After Surgery: Overall Response
Overall response was based on neuroimaging (magnetic resonance imaging \[MRI\]), clinical neurological examination, and steroid administration. It was assessed as follows: Complete Response (CR): Disappearance of all enhancing tumor (measurable or non-measurable), no corticosteroid use, and neurologically stable or improved. Partial Response (PR): ≥50% reduction in size of enhancing tumor (measurable or non-measurable) for any measurable lesions or definite improvement for any non-measurable lesions, corticosteroid dosage stable or reduced, and neurologically stable or improved. Progressive Disease (PD): ≥25% increase in contrast enhancement for any measurable lesions or definite worsening for any non-measurable lesions, or any new tumor on MRI scans, at an increased dose of corticosteroid, with or without neurologic progression. Clinical or radiological worsening resulting from other than tumor factors were excluded. Stable Disease (SD): All other situations.
Time frame: Up to 2 years
Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group
MGMT was measured by immunohistochemistry (IHC). OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.
Time frame: Up to 2 years
Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group
MGMT was measured by IHC. OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.
Time frame: Up to 2 years
Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Positive Group
MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.
Time frame: 6, 12, & 18 months
Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Negative Group
MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.
Time frame: 6, 12, & 18 months
Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group
MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.
Time frame: Up to 2 years
Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group
MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.
Time frame: Up to 2 years
| Milestone | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| Started | 47 | 52 |
| Completed | 1 | 10 |
| Not completed | 46 | 42 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Progressive disease | 17 | 23 |
| Withdrew: Lost to follow-up | 7 | 5 |
| Withdrew: Death | 6 | 3 |
| Withdrew: Withdrawal by subject | 13 | 4 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Other | 1 | 3 |
OS was defined as the time from randomization to death. OS was calculated by the Kaplan-Meier method.
| months | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| Overall Survival (OS) | 13.17 (11.14 to 18.76) | 17.58 (15.18 to 23.03) |
PFS was defined as the length of time from randomization to disease progression (the length of time during which the cancer did not get worse) or death. PFS was calculated by the Kaplan-Meier method.
| months | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| Progression-Free Survival (PFS) | 10.38 (8.18 to 15.44) | 8.74 (6.41 to 14.85) |
Overall response was based on neuroimaging (magnetic resonance imaging \[MRI\]), clinical neurological examination, and steroid administration. It was assessed as follows: Complete Response (CR): Disappearance of all enhancing tumor (measurable or non-measurable), no corticosteroid use, and neurologically stable or improved. Partial Response (PR): ≥50% reduction in size of enhancing tumor (measurable or non-measurable) for any measurable lesions or definite improvement for any non-measurable lesions, corticosteroid dosage stable or reduced, and neurologically stable or improved. Progressive Disease (PD): ≥25% increase in contrast enhancement for any measurable lesions or definite worsening for any non-measurable lesions, or any new tumor on MRI scans, at an increased dose of corticosteroid, with or without neurologic progression. Clinical or radiological worsening resulting from other than tumor factors were excluded. Stable Disease (SD): All other situations.
| participants | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| CR | 1 | 0 |
| PR | 0 | 0 |
| SD | 38 | 47 |
| PD | 3 | 4 |
| No overall response data available | 5 | 1 |
MGMT was measured by immunohistochemistry (IHC). OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.
| months | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group | 14.4 ± 2.385 | 17.49 ± 1.491 |
MGMT was measured by IHC. OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.
| months | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group | 13.81 ± 1.417 | 15.12 ± 1.171 |
MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.
| percentage of participants | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| 6 months | 80.8 (42.3 to 94.9) | 89.2 (63.1 to 97.2) |
| 12 months | 69.3 (31.2 to 89.1) | 82.8 (55.4 to 94.2) |
| 18 months | 36.9 (6.5 to 69.6) | 66.2 (35.7 to 84.8) |
MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.
| percentage of participants | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| 6 months | 87.5 (66.1 to 95.8) | 95.8 (73.9 to 99.4) |
| 12 months | 57.7 (31.9 to 76.8) | 81.4 (57.5 to 92.6) |
| 18 months | 44.9 (21.1 to 66.3) | 26.7 (9.1 to 48.3) |
MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.
| months | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group | 10.04 ± 2.094 | 11.19 ± 1.882 |
MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.
| months | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation |
|---|---|---|
| Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group | 11.11 ± 1.441 | 10.46 ± 1.475 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Temozolomide Radiation | — | 11/42 (26.2%) | 24/42 (57.1%) |
| Temozolomide Alone, Then Temozolomide Radiation | — | 11/52 (21.2%) | 22/52 (42.3%) |
| Event | Temozolomide Radiation | Temozolomide Alone, Then Temozolomide Radiation |
|---|---|---|
| NEOPLASM RECURRENCENeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/42 | 5/52 |
| DISEASE PROGRESSIONGeneral disorders | 3/42 | 2/52 |
| NAUSEAGastrointestinal disorders | 1/42 | 0/52 |
| VOMITINGGastrointestinal disorders | 1/42 | 0/52 |
| DISEASE RECURRENCEGeneral disorders | 1/42 | 0/52 |
| HEPATIC FAILUREHepatobiliary disorders | 1/42 | 0/52 |
| EPILEPSYNervous system disorders | 1/42 | 0/52 |
| HEADACHENervous system disorders | 1/42 | 0/52 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 1/42 | 1/52 |
| CENTRAL NERVOUS SYSTEM INFECTIONInfections and infestations | 0/42 | 1/52 |
| Event | Temozolomide Radiation | Temozolomide Alone, Then Temozolomide Radiation |
|---|---|---|
| NAUSEAGastrointestinal disorders | 13/42 | 7/52 |
| VOMITINGGastrointestinal disorders | 12/42 | 4/52 |
| HEADACHENervous system disorders | 10/42 | 2/52 |
| PYREXIAGeneral disorders | 5/42 | 3/52 |
| DECREASED APPETITEMetabolism and nutrition disorders | 4/42 | 2/52 |
| DIZZINESSNervous system disorders | 0/42 | 4/52 |
| EPILEPSYNervous system disorders | 1/42 | 4/52 |
| GAIT DISTURBANCEGeneral disorders | 3/42 | 0/52 |
| CONSTIPATIONGastrointestinal disorders | 0/42 | 3/52 |
| INTRACRANIAL PRESSURE INCREASEDNervous system disorders | 0/42 | 3/52 |
| Age, Continuous(years) | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation | Total |
|---|---|---|---|
| Mean | 52.1 ± 10.12 | 48.5 ± 13.04 | 50.2 ± 11.82 |
| Sex: Female, Male(Participants) | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation | Total |
|---|---|---|---|
| Female | 13 | 20 | 33 |
| Male | 34 | 32 | 66 |
| Region of Enrollment(participants) | Temozolomide + Radiation | Temozolomide Alone, Then Temozolomide + Radiation | Total |
|---|---|---|---|
| China | 47 | 52 | 99 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jun 2008 to primary completion in Sep 2011, 39 months.
Results were first posted in Apr 2013, 1 year 6 months after primary completion. A results delay was requested in Sep 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide